Schizotypal Personality Disorder Risperidone

Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau

Status and phase: Completed; Phase 2; Phase 1

Conditions: Schizotypal Personality Disorder

Treatments: Drug: Placebo; Drug: Risperidone

Study type: Interventional

Funder types: Other

Identifiers

NCT02535156

CIM/02/112/01

Details and patient eligibility

About

Neurophysiological indices of self-monitoring were assessed in a group of patients with Schizotypal Personality Disorder (SPD) and a control group. Both groups were assessed after the administration of risperidone and placebo.

Full description

The electroencephalogram (EEG) was recorder while participants (SPD participants and controls) performed a behavioral task: the Eriksen Flanker Task. The continuous EEG was segmented, corrected for artifacts and averaged. A component of the event-related brain potential known as the error-related negativity (ERN) was identified and its amplitude quantified in microvolts.

This procedure was conducted two hours after the administration of risperidone 1 mg and placebo (lactose) on two different experimental days and for each participant group (SPD patients and controls).

The amplitude of the ERN after placebo was compared between groups to test for baseline (non-drug-induced) differences between patients and controls.

The impact of risperidone on the amplitude of the ERN was compared between the two participant groups.

Enrollment: 21 patients

Sex: All

Ages: 18+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Schizotypal Personality Disorder

Exclusion criteria

• Major Psychiatric Disorder
• Medical condition

Trial design

Primary purpose: Basic Science

Allocation: Non-Randomized

Interventional model: Crossover Assignment

Masking: Double Blind

---

21 participants in 2 patient groups

Schizotypal Personality Disorder

Experimental group

Description:

Schizotypal Personality Disorder (SPD) patients. They received two interventions: risperidone 1 mg and placebo (lactose).

Treatment:

Drug: Risperidone

Drug: Placebo

Healthy controls

Experimental group

Description:

Control group consisting of healthy volunteers.They received two interventions: risperidone 1 mg and placebo (lactose).

Treatment:

Drug: Risperidone

Drug: Placebo